组蛋白去乙酰化酶抑制剂治疗血液肿瘤的研究进展
摘要
组蛋白乙酰转移酶（HAT）及组蛋白去乙酰化酶（HDAC）控制组蛋白乙酰化状态，重塑染色质表观遗传，分别抑制和促进基因表达。组蛋白去乙酰化酶抑制剂（HDACI）可抑制肿瘤细胞生长，诱导其凋亡。多种HDACI正在进行I期和Ⅱ期临床试验，在治疗血液肿瘤方面显示出潜在的抗肿瘤活性及良好的耐受性。
出处
《国际输血及血液学杂志》
CAS
2012年第3期219-223,共5页
International Journal of Blood Transfusion and Hematology
基金
国家自然科学基金（30872982,81172252）
参考文献30
-
1Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet, 2002, 32(4) : 606-613.
-
2Stephen S, Andy IC, Craig O, vorinostat (SAHA), eladribine et al. A phase Ⅰ/Ⅱ study of (2-CdA), and rituximab shows significant activity in previously untreated mantle cell lymphoma Blood, 2011, 118:441.
-
3Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat ( suberoylanilide hydroxamic acid, SAHA ) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 2007, 109 (1) : 31- 39.
-
4Olsen EA, Kim YH, Kuzel TM, et al. Phase Ⅱ b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Onto1, 2007, 25(21):3109-3115.
-
5Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res, 2008, 68(10) ;3785-3794.
-
6Kirschbaum M, Frankel P, Popplewell L, et al. Phase Ⅱ study of vorinostat for treatment of relapsed or refractory indolent non- Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol, 2011, 29(9) :1198-1203.
-
7Zain JM, Foss F, Kelly WK, et al. Final results of a phase Ⅰ study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol, 2009, 27 (15s):8580.
-
8Jasmine MZ, Francine MF, Catherine SD, et al. Preliminary results of an ongoing phase Ⅰ trial of oral belinostat a novel histone deacetylase inhibitor in patients with lymphoid malignancies. Blood, 2011, 118 : 3710.
-
9Pohlman B, Advani R, Duvic M, et al. Final results of a phase Ⅱ trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T cell lymphoma. Blood, 2009, 114(22) :920.
-
10Prince HM, George DJ, Patnaik A, et al. Phase study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and Non-Hodgkin~s lymphoma. J Clin Oncol, 2007, 25 (Suppl) : 18s.
-
1王丹丹,何红鹏,张同存.组蛋白乙酰转移酶p300对人乳腺癌细胞迁移的影响[J].天津科技大学学报,2015,30(6):1-6.
-
2王楠,阎征,刘娜.组蛋白去乙酰酶抑制剂的药理学研究进展[J].中国新药杂志,2004,13(7):594-598. 被引量：2
-
3常锐,尤嘉琮,周清华.HATs与HDACs在肺癌上皮细胞间质转化中作用机制及其应用的研究进展[J].中国肺癌杂志,2013,16(4):211-215. 被引量：5
-
4王恩旺,杨小龙.p300/CBP与肺癌[J].中国肺癌杂志,2009,12(8):926-930. 被引量：5
-
5刘春艳,孙海晶,陆军,黄百渠.组蛋白乙酰化与癌症[J].生物化学与生物物理进展,2003,30(1):19-23. 被引量：10
-
6贾敏,纪木火,杨建军,徐建国.组蛋白去乙酰化酶在认知功能障碍中的作用[J].临床麻醉学杂志,2014,30(3):306-308. 被引量：1
-
7孟祥熙,白晓东,胡森.组蛋白去乙酰化酶抑制剂抗炎机制的研究进展[J].感染．炎症．修复,2014,15(3):186-189.
-
8龙娟,闫征,赵晋燕,王楠.新结构组蛋白去乙酰化酶抑制剂筛选及抗肿瘤活性初步观察[J].中国药理通讯,2005,22(3):29-29.
-
9徐君,林怡翔,顾若漪,王慧君,马晓静,马端,黄国英.法洛四联症患儿组蛋白乙酰化及其酶的表达[J].中国当代儿科杂志,2013,15(10):817-821. 被引量：4
-
10白慧颖,胡森,冀文茹.组蛋白去乙酰化酶抑制剂的研究进展[J].感染．炎症．修复,2009,10(3):187-189. 被引量：3
